Pheochromocytoma: Clinical Trials

21 trials for Pheochromocytoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 6 completed, 3 terminated, 3 withdrawn. 21 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 121Recruiting 8, Completed 6, Terminated 3, Withdrawn 3, Not yet recruiting 1
Phase 27Recruiting 4, Completed 1, Terminated 1, Withdrawn 1

Follow Pheochromocytoma: new trials by email Literature Review of Pheochromocytoma trials Research Report on Pheochromocytoma

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
211At-MABG in Adults With Advanced Neuroendocrine Cancers
1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma
Phase 1Not yet recruitingUniversity of Pennsylvania162026-12-012026-10-07
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
Phase 1RecruitingAnusha Kalbasi182025-10-072026-03-17
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
[212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma
Phase 1RecruitingNational Cancer Institute (NCI)1202025-08-192026-10-06
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)662025-02-072026-10-16
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma
Phase 1 / Phase 2RecruitingFundación de investigación HM252024-09-202026-06-04
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
ADCT-701 - Neuroendocrine Carcinomas, Neuroendocrine Tumors
Phase 1RecruitingNational Cancer Institute (NCI)702024-06-172026-11-09
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
[203Pb]VMT-α-NET, [212Pb]VMT-α-NET - Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Phase 1 / Phase 2RecruitingPerspective Therapeutics3002023-09-272026-10-13
HTL0039732 in Participants With Advanced Solid Tumours
HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion - Neoplasms, Prostatic Neoplasms, Castration-Resistant
Phase 1 / Phase 2RecruitingCancer Research UK1502023-08-022026-10-01
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
DFF332, RAD001, PDR001 - Carcinoma, Renal Cell
Phase 1TerminatedNovartis Pharmaceuticals402021-11-302026-03-03
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma
Phase 1 / Phase 2WithdrawnSue O'Dorisio2020-08-042021-06-08
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
EO2401, Nivolumab - Adrenocortical Carcinoma, Pheochromocytoma
Phase 1 / Phase 2TerminatedEnterome702020-07-232026-01-30
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Phase 1WithdrawnVanderbilt-Ingram Cancer Center2017-12-012017-09-28
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Vandetanib, 131I-mIBG - Phaeochromocytoma, Paraganglioma
Phase 1WithdrawnUniversity College, London2014-10-012015-12-21
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Phase 1CompletedUniversity of Southern California192010-06-012016-06-13
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Ultratrace Iobenguane (MIBG) I 131 - Pheochromocytoma, Paraganglioma
Phase 1 / Phase 2CompletedMolecular Insight Pharmaceuticals, Inc.242007-04-012016-07-13
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Ultratrace iobenguane I 131 - Pheochromocytoma, Paraganglioma
Phase 1CompletedMolecular Insight Pharmaceuticals, Inc.242006-06-012011-10-12
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma
Phase 1CompletedMayo Clinic962004-12-012024-08-21
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
90Y-DOTA-tyr3-OCTREOTIDE - Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Phase 1CompletedO'Dorisio, M S272002-01-012016-06-21
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
floxuridine, leucovorin calcium, oxaliplatin - Cancer
Phase 1CompletedMemorial Sloan Kettering Cancer Center2000-04-012011-04-26
Diagnosis of Pheochromocytoma
([18F]-DOPA), ([18F]-6F-DA) - Pheochromocytoma, Endocrine Disease
Phase 1RecruitingEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)30002000-03-222026-10-08

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Paraganglioma (13)  ·  Neuroendocrine Tumors (10)  ·  Carcinoma, Islet Cell (5)  ·  Carcinoma, Medullary (5)  ·  Insulinoma (5)  ·  Carcinoma, Merkel Cell (4)  ·  Carcinoma, Renal Cell (4)  ·  Gastrinoma (4)  ·  Glucagonoma (4)  ·  Neuroblastoma (4)  ·  Somatostatinoma (4)  ·  Adenoma, Islet Cell (3)  ·  Adrenocortical Carcinoma (3)  ·  Esthesioneuroblastoma, Olfactory (3)

Broader conditions

Neoplasms by Histologic Type (21)  ·  Neoplasms, Germ Cell and Embryonal (21)  ·  Neoplasms, Nerve Tissue (21)  ·  Neuroectodermal Tumors (21)  ·  Neoplasms (18)  ·  Neoplasms, Glandular and Epithelial (15)  ·  Neoplasms by Site (14)  ·  Carcinoma (13)  ·  Adenocarcinoma (12)  ·  Endocrine Gland Neoplasms (11)  ·  Endocrine System Diseases (11)  ·  Neuroendocrine Tumors (11)  ·  Digestive System Diseases (8)  ·  Digestive System Neoplasms (8)  ·  Pancreatic Diseases (8)

Interventions

3-Iodobenzylguanidine (2)  ·  Everolimus (2)  ·  gallium Ga 68 dotatate (2)  ·  lutetium Lu 177 dotatate (2)  ·  6-fluorodopamine (1)  ·  Biopsy (1)  ·  Capecitabine (1)  ·  Cyclophosphamide (1)  ·  Floxuridine (1)  ·  Fluorodeoxyglucose F18 (1)  ·  High-Energy Shock Waves (1)  ·  Interleukin-13 (1)  ·  Iodine-131 (1)  ·  Leucovorin (1)  ·  Magnetic Resonance Spectroscopy (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Molecular Insight Pharmaceuticals, Inc. (2)  ·  Anusha Kalbasi (1)  ·  Cancer Research UK (1)  ·  Enterome (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Fundación de investigación HM (1)  ·  Mayo Clinic (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Novartis Pharmaceuticals (1)  ·  O'Dorisio, M S (1)  ·  Perspective Therapeutics (1)  ·  Sue O'Dorisio (1)  ·  University College, London (1)  ·  University of Pennsylvania (1)

Countries

United States (16)  ·  Spain (3)  ·  France (2)  ·  Italy (2)  ·  United Kingdom (2)  ·  Czechia (1)  ·  Denmark (1)  ·  Germany (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  Sweden (1)

Top investigators

Frank I Lin, M.D. (2)  ·  M. Sue O'Dorisio, MD, PhD (2)  ·  Agustin Garcia (1)  ·  Allison Betof Warner, MD, PhD (1)  ·  Antoni Ribas, MD, PhD (1)  ·  Catherine M Gordon, M.D. (1)  ·  Christina Thirlwell (1)  ·  Jaydira Del Rivero, M.D. (1)  ·  Jean-Michel Paillarse (1)  ·  John R. Murren, MD (1)  ·  Jordan Berlin, M.D. (1)  ·  Julian R. Molina, M.D., Ph.D. (1)  ·  Leonard B. Saltz, MD (1)  ·  Marta Osuna Marco, PhD (1)

Results publications

PMID 20847174, PMID 29099942, PMID 29534198, PMID 31057686, PMID 31231443, PMID 34431366, PMID 39416174, PMID 40595495, PMID 42558019

NIH funding

R01CA300202 (1)